Back

Tolerance and clinical response to SGL2 inhibitors in Fabry disease

12 May 2024 (15:24 - 17:00)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - pharmacotherapy 3 Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Isabel Mattig

German Heart Centre Berlin, Berlin (Germany)

4 More presentations in this session

Presentation thumbnail
The role of intermittent levosimendan infusions in patients with advanced heart failure: is it enough?
Doctor I. Gomes Campos (Penafiel, PT)
Abstract Slides Video
Presentation thumbnail
Predictors of complete evidence-based treatment implementation at hospital discharge of acute heart failure with reduced LVEF in a real-world population
Doctor S. Ruiz Bustillo (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
12-Month effect of Tafamidis on the clinical progression of cardiac amyloidosis in a single centre cohort
Doctor R. Carvalheiro (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Optimizing heart failure management: impact of quadruple therapy initiation at discharge following decompensation events in patients with reduced ejection fraction
Doctor C. Gregorio (Lisbon, PT)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - pharmacotherapy 3

The Event

Event poster

Heart Failure 2024

12 May 2024 15:24 CET
You may be interested in
thumbnail
Congress Presentation
SGLT2i on transthyretin amyloid cardiomyopathy - a new drug for an under-recognized cardiomyopathy
thumbnail
Congress Presentation
SGLT2 inhibitor treatment in patients with cardiac amyloidosis
thumbnail
Congress Session
Further Insights into SGLT2i treatment for heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources